+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Drug design targeting the main protease, the Achilles' heel of coronaviruses



Drug design targeting the main protease, the Achilles' heel of coronaviruses



Current Pharmaceutical Design 12(35): 4573-4590



Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M(pro)), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M(pro)s. It is expected that inhibitors targeting CoV M(pro)s could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048833273

Download citation: RISBibTeXText

PMID: 17168763


Related references

Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses. Current Pharmaceutical Design 12(35): 4573-4590, 2006

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease. Protein and Cell 4(4): 248-250, 2013

Targeting the Achilles' heel of drug-resistant cancer stem cells. Cell Cycle 13(13): 2017-2018, 2014

Targeting the Achilles' heel of hepatitis C virus. Hepatology 25(4): 1035-1037, 1997

Targeting autophagy: the Achilles' heel of cancer. Autophagy 8(8): 1279-1280, 2012

Cancer angiogenesis: targeting the heel of Achilles. Journal of Drug Targeting 16(6): 449-454, 2008

Targeting Developmental Pathways: The Achilles Heel of Cancer?. Oncology 93(4): 213-223, 2017

Targeting an Achilles' heel of cancer with a WRN helicase inhibitor. Cell Cycle 12(20): 3329-3335, 2013

Targeting EBV's Achilles' heel with antigen-specific T cells. ImmunoTherapy 5(4): 353-355, 2013

CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Experimental Hematology 52: 1-11, 2017

Experimental therapeutics: targeting the redox Achilles heel of cancer. Current Opinion in Investigational Drugs 8(12): 1022-1037, 2007

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica. B 8(4): 552-562, 2018

Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet. Infectious Diseases 5(11): 726-731, 2005

Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antiviral Chemistry & ChemoTherapy 15(3): 135-140, 2004

Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus. Molecular Microbiology 98(1): 7, 2015